Transfusion-associated Graft-versus-Host Disease in an Immunocompetent Patient
Authors: Stephen M. Capon, William D. DePond, Dolly B. Tyan, Samuel H. Pepkowitz, Hiroo Toyoda, Arnold C. Cinman, Paul C. Azer, Dennis Goldfinger
Journal: Annals of Internal Medicine (1991)

Brief Report15 June 1991Transfusion-associated Graft-versus-Host Disease in an Immunocompetent PatientStephen M. Capon, MD, William D. DePond, MD, Dolly B. Tyan, MA, Samuel H. Pepkowitz, MD, Hiroo Toyoda, PhD, Arnold C. Cinman, MD, Paul C. Azer, MD, Dennis Goldfinger, MDStephen M. Capon, MDSearch for more papers by this author, William D. DePond, MDSearch for more papers by this author, Dolly B. Tyan, MASearch for more papers by this author, Samuel H. Pepkowitz, MDSearch for more papers by this author, Hiroo Toyoda, PhDSearch for more papers by this author, Arnold C. Cinman, MDSearch for more papers by this author, Paul C. Azer, MDSearch for more papers by this author, Dennis Goldfinger, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-114-12-1025 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTransfusion-associated graft-versus-host disease (TAGVHD) is a rare complication of transfusion (1) that occurs when immunocompetent donor lymphocytes attack host tissues expressing foreign histocompatibility antigens. Until recently, it was believed that only transfusion recipients with profound defects in cellular immunity were susceptible to TA-GVHD. However, there have now been reports of TA-GVHD occurring in immunocompetent patients (2, 3). In each, one blood donor possessed an HLA phenotype consisting entirely of antigens shared by the recipient, whereas the recipient expressed additional HLA antigens not shared by the donor. Transfusion-associated graft-versus-host disease appeared to develop because recipient lymphocytes were genetically incapable of mounting...References1. von FliednerHigbyKim VDU. Graft-versus-host reaction following blood product transfusion. Am J Med. 1982;72:951-61. CrossrefMedlineGoogle Scholar2. ThalerShamissOrgad MAS. The role of blood from HLA-homozygous donors in fatal transfusion-associated graft-versus-host disease after open-heart surgery. N Engl J Med. 1989;321:25-8. CrossrefMedlineGoogle Scholar3. ItoYoshidaYanagibashi KHK. Change of HLA phenotype in postoperative erythroderma [Letter]. Lancet 1988;1:413-4. CrossrefMedlineGoogle Scholar4. LizakGrumet GF. A new micromethod for the in vitro detection of antiplatelet antibodies: C-FDA thrombocytotoxicity. Hum Immunol. 1980;1:87-96. CrossrefMedlineGoogle Scholar5. VartdalGaudernackFunderud FGS. HLA class I and II typing using cells positively selected from blood by immunomagnetic isolation—a fast and reliable technique. Tissue Antigens. 1986;28:301-12. CrossrefMedlineGoogle Scholar6. ToyodaOnohara-ToyodaKrull HMJ. Application of synthetic oligonucleotides to detect DQ beta genes transmission within insulin-dependent diabetes families. Dis Markers. 1989;7:215-28. MedlineGoogle Scholar7. KruskallAlperAwdehYunis MCZE. HLA-homozygous donors and transfusion-associated graft-versus-host disease [Letter]. N Engl J Med. 1990;322:1005-6. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: From the Cedars-Sinai Medical Center, Los Angeles, California. For current author addresses, see end of text. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByTransfusion in TransplantationManifestations and Treatment of Acute Graft-versus-Host DiseaseTransfusion-Associated Graft Versus Host Disease in the Immunocompetent PatientDrug ReactionsIrradiated ProductsQuantitative flow cytometry in the clinical laboratoryTransfusion TherapyHazards of Transfusion: GvHDIrradiated ProductsPrevention of transfusion-associated graft-versus-host disease by inactivation of T cells in platelet componentsPharmacokinetic and toxicology assessment of INTERCEPT (S-59 and UVA treated) plateletsREVISITATION OF THE CLINICAL INDICATIONS FOR THE TRANSFUSION OF PLATELET CONCENTRATESInactivation of WBCs in RBC suspensions by photoactive phenothiazine dyes: comparison of dimethylmethylene blue and MBPrevention of Transfusion-Associated Graft-Versus-Host Disease by Photochemical TreatmentInactivation of Leukocytes in Platelet Concentrates by Photochemical Treatment With Psoralen Plus UVABlood Transfusion Reaction, Diagnosis, and TreatmentTransfusion-associated chronic cutaneous graft-versus-host diseaseNoninfectious Complications of Blood TransfusionSuccessful treatment of transfusion-associated graft-versus-host diseasePolymorphic Microsatellite Markers for the Diagnosis of Graft-versus-Host DiseaseHLA Homozygosity and Shared HLA Haplotypes in the Development of Transfusion-Associated Graft-Versus-Host DiseaseAnalysing early liver dysfunction after bone marrow transplantationTransfusion-associated graft-versus-host disease in immunocompetent patients: report of a fatal case associated with transfusion of blood from a second-degree relative, and a survey of predisposing factorsPosttransfusion graft-versus-host disease in two immunocompetent patientsGraft-versus-Host Disease Associated with Transfusion of Blood from Unrelated HLA-Homozygous DonorsHLA Homozygosity and the Risk of Related-Donor Transfusion-Associated Graft-Versus-Host Diseaseleukocyte-reduced blood components in transfusion medicine: Current Indications and Prospects for the FutureSpecial Issues in Transfusion MedicineTransfusion associated graft versus host disease in an immunocompetent patient.Transfusion-Associated Graft-Versus-Host Disease and Blood Irradiation 15 June 1991Volume 114, Issue 12Page: 1025-1026KeywordsAntigensGenetic diseasesHuman leukocyte antigenImmunityLymphocytesMajor histocompatibility antigensMedical geneticsPathology and laboratory medicinePhenotypesTransfusion medicine Issue Published: 15 June 1991 PDF DownloadLoading ...